Oncolab (Romania)

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee et al. · European Journal of Cancer · 2019 · 217 citations · Full text

Medicine, Oncology, Pharmacology +17

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Salomon M. Stemmer, Nebojša Manojlović, Mihai Vasile Marinca et al. · Cancers · 2021 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)

Rathi N. Pillai, Dean A. Fennell, Vladimir Kovčin et al. · Journal of Thoracic Oncology · 2017 · 15 citations

Medicine, Oncology, Pharmacology +14

A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A₃ adenosine receptor agonist (A₃AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Salomon M. Stemmer, Nebojša Manojlović, Mihai Vasile Marinca et al. · Journal of Clinical Oncology · 2019 · 11 citations

Medicine, Oncology, Pharmacology +13